Scientists develop novel combination therapy for treating vancomycin-resistant bacterial infections

Low-Res_A confocal microscopy image of macrophages treated with MTX (cyan) that have eaten bacteria (magenta).png

Source: Singapore-MIT Alliance for Research and Technology (SMART)

Researchers have developed a novel combination therapy using an anticancer agent, mitoxantrone (MTX), together with an antibiotic, vancomycin, for treating bacteria that are resistant to the vancomycin.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE